Rituximab as first line treatment for MALT lymphoma of extraocular muscles.
Benetatos
Leonidas
L
Alymara
Vasiliki
V
Asproudis
Ioannis
I
Bourantas
Konstantinos L
KL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009801:Oculomotor Muscles / Q000473:pathology; D012074:Remission Induction; D000069283:Rituximab; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab